Chromeceptin is a cell-permeable benzochromene compound that blocks insulin-induced adipogenesis in 3T3-L1 cells (100% blockage at ≤ 20 ng/μl) and selectively suppresses IGF2- (insulin-like growth factor 2) dependent growth of HepG2 carcinoma cells (IC50 = 29 nM). Chromeceptin has been shown to bind to MFP-2 (multifunctional protein-2) and activate STAT6-mediated gene expression, such as IGFBP-1 and SOCS-3, in HepG2 cells.
